Equities

Blue Jet Healthcare Ltd

BLUEJET:NSI

Blue Jet Healthcare Ltd

Actions
Health CarePharmaceuticals and Biotechnology
  • Price (INR)448.45
  • Today's Change2.05 / 0.46%
  • Shares traded198.48k
  • 1 Year change--
  • Beta--
Data delayed at least 15 minutes, as of Jul 29 2024 09:07 BST.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Profile data is unavailable for this security.

About the company

Blue Jet Healthcare Limited is an India-based specialty pharmaceutical and healthcare ingredients and intermediates company. The Company’s operations are primarily organized in three product categories: contrast media intermediates, high-intensity sweeteners, and pharma intermediates and active pharmaceutical ingredients (APIs). Contrast media are agents used in medical imaging to enhance the visibility of body tissues under X-rays, computed tomography (CT), magnetic resonance imaging (MRI) or ultrasound. Its high-intensity sweetener business includes development, manufacturing and marketing of saccharin and its salts. The Company’s contract development and manufacturing organization (CDMO) activity in the pharma intermediate and API business is primarily focused on collaborating with innovator pharmaceutical companies and multi-national generic pharmaceutical companies by providing them with pharma intermediates that serve as building blocks for APIs in chronic therapeutic areas.

  • Revenue in INR (TTM)7.12bn
  • Net income in INR1.64bn
  • Incorporated1968
  • Employees--
More ▼

Peer analysis

Key Information
CompanyRevenue (TTM)Net income (TTM)Market capEmployeesPrice/earnings (TTM)Price/book value (MRQ)Price/cash flow (TTM)Price/sales (TTM)EPS (excl. extraordinary items, TTM)EPS (incl. extraordinary items, TTM)Revenue per share (TTM)Book value per share (MRQ)Asset turnover (TTM)Inventory turnover (TTM)Receivables turnover (TTM)Revenues per employee (TTM)Return on avg assets (TTM)Return on avg assets (5 yr avg)Return on investment (TTM)Return on investment (5 yr avg)Gross margin (TTM)Gross margin
(5 yr avg)
Net profit margin (TTM)Net Profit margin
(5 yr avg)
Quick ratio (MRQ)Interest coverage (TTM)Total debt to capital (MRQ)Payout ratio
(5 yr avg)
Revenue
(YOY change %)
Revenue
(5 yr growth rate)
Net income
(YOY change %)
Net income
(5 yr growth rate)
Capital expenditure
(5 yr growth rate)
Dividend
(5 yr growth rate)
Hikal Ltd17.85bn696.00m44.03bn2.14k63.203.7123.522.475.655.65144.7796.320.73252.663.60--2.865.074.037.5153.7947.223.905.860.87612.650.407716.88-11.792.34-11.20-7.559.720.00
Aarti Drugs Ltd25.29bn1.71bn48.42bn1.50k28.303.7821.711.9118.6118.61274.44139.401.043.353.22--7.079.7310.9815.7433.6524.966.798.251.057.910.3056---6.9010.133.0713.8224.96--
Aarti Pharmalabs Ltd18.53bn2.17bn54.85bn1.63k25.283.1218.902.9623.9423.94204.48193.880.76981.633.8611,386,720.009.01--12.30--44.90--11.71--1.0018.770.1397---4.76--12.10------
Shilpa Medicare Ltd11.51bn318.74m65.08bn1.03k180.863.1946.555.653.683.68134.51208.370.38411.233.21--1.072.841.413.6564.6361.372.787.030.76711.410.3424--9.669.44198.15-22.26-9.26--
Orchid Pharma Ltd8.19bn915.95m72.69bn838.0074.886.2256.918.8719.1419.14169.90230.580.58971.973.99--6.80-0.97348.80-1.4040.8743.3211.53-2.402.034.680.1036--23.056.4373.595.8457.79--
Sun Pharma Advanced Research Co Ltd755.45m-3.87bn73.56bn409.00--58.49--97.37-11.93-11.932.333.880.112322.112.321,847,073.00-57.57-61.70-85.94-119.3162.7674.49-512.56-163.401.01-244.660.3272---68.36-16.21-73.96--15.40--
Blue Jet Healthcare Ltd7.12bn1.64bn77.43bn--47.279.1640.3610.889.449.4441.0448.730.74092.463.42--17.05--21.25--55.82--23.01--2.801,257.130.00---1.30--2.33------
F D C Ltd19.43bn3.05bn81.75bn6.37k26.983.9023.704.2118.6118.61118.69128.810.80771.8316.19--12.6812.0514.5613.7366.2362.8115.7015.852.1874.020.0097--8.9212.2457.3012.4516.93--
Procter & Gamble Health Ltd11.69bn2.14bn86.88bn1.41k40.62--36.087.43128.85128.85703.49--------8,305,331.00--------70.45--18.31----400.33----10.34--19.19------
Marksans Pharma Ltd21.77bn3.14bn90.78bn1.40k28.914.4023.334.176.936.9348.1145.570.8941.885.01--12.9314.6215.3618.5252.3251.2214.4614.033.1934.300.10486.6617.5616.8417.8032.6273.8664.38
Strides Pharma Science Ltd40.51bn-1.25bn93.90bn2.85k--4.42130.152.32-13.86-7.93445.06231.290.64931.443.32---2.38-1.68-4.43-2.9759.5052.74-3.67-3.360.641.070.5485--9.8313.2143.57---18.52-3.58
Glenmark Life Sciences Ltd22.93bn4.47bn104.23bn1.82k23.36--20.764.5436.4136.41186.83------------18.28--30.0354.5853.4019.4920.23--389.45----5.6420.830.84119.2169.11--
Neuland Laboratories Ltd.15.59bn3.00bn107.48bn1.65k35.828.3829.876.90233.89233.891,214.81999.780.91352.334.249,457,406.0017.599.2523.5812.7152.9247.8119.2511.991.3328.780.06927.1330.8418.5183.5178.7617.8863.45
Jubilant Pharmova Ltd68.48bn5.53bn114.73bn1.03k20.77--12.321.6834.8934.89431.45------------2.96--3.5568.1369.378.015.13--2.34--24.696.70-5.95226.43-33.086.482.13
Caplin Point Laboratories Ltd16.94bn4.57bn116.10bn777.0025.505.0122.556.8559.9059.90222.01304.930.69312.223.62--18.8819.8321.8022.8257.2553.9927.2425.394.63976.470.0008--15.5021.1721.4820.9517.47--
Data as of Jul 29 2024. Currency figures normalised to Blue Jet Healthcare Ltd's reporting currency: Indian Rupee INR

Institutional shareholders

3.23%Per cent of shares held by top holders
HolderShares% Held
Norges Bank Investment Managementas of 31 Dec 20233.28m1.89%
ICICI Prudential Asset Management Co. Ltd.as of 30 Jun 2024990.47k0.57%
Aditya Birla Sun Life Insurance Co. Ltd.as of 30 Jun 2024478.59k0.28%
HDFC Asset Management Co. Ltd. (Invt Mgmt)as of 30 Jun 2024367.34k0.21%
Edelweiss Asset Management Ltd.as of 30 Jun 2024300.53k0.17%
Bandhan Asset Management Co. Ltd.as of 30 Jun 2024144.80k0.08%
Motilal Oswal Asset Management Co. Ltd.as of 30 Jun 202442.39k0.02%
Groww Asset Management Ltd.as of 30 Jun 2024223.000.00%
More ▼
Data from 31 Dec 2023 - 15 Jul 2024Source: FactSet Research Systems Inc.
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.